MedElevator
Войти в исследования American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siegal Deborah M, Tseng Eric K, Schünemann Holger J, Angchaisuksiri Pantep, Cuker Adam, Dane Kathryn, DeSancho Maria T, Diuguid David, Griffin Daniel O, Klok Frederikus A, Lee Alfred Ian, Neumann Ignacio, Pai Ashok, Righini Marc, Sanfilippo Kristen M, Terrell Deirdra R, Akl Elie A, Al Jabiri Reyad, Al Jabiri Yazan, Barbara Angela M, Bognanni Antonio, Akl Imad Bou, Boulos Mary, Brignardello-Petersen Romina, Chan Matthew, Charide Rana, Colunga-Lozano Luis E, Dearness Karin, Darzi Andrea J, Hussein Heba, Karam Samer G, Kolb Philipp, Mansour Razan, Morgano Gian Paolo, Morsi Rami Z, Muti-Schünemann Giovanna, Nadim Menatalla K, Noori Atefeh, Philip Binu A, Piggott Thomas, Qiu Yuan, Benitez Yetiani Roldan, Schünemann Finn, Stevens Adrienne, Solo Karla, Wiercioch Wojtek, Mustafa Reem A, Nieuwlaat Robby
Аннотация
METHODS: ASH formed a multidisciplinary panel, including patient representatives. The Michael G. DeGroote Cochrane Canada and MacGRADE Centres at McMaster University supported guideline development, including performing systematic reviews (up to June 2023). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess certainty in the evidence and make recommendations.
RESULTS: This is an executive summary of 3 updated recommendations that have been published, which concludes the living phase of the guidelines. For patients with COVID-19-related critical illness, the panel issued conditional recommendations suggesting (a) prophylactic-intensity over therapeutic-intensity anticoagulation and (b) prophylactic-intensity over intermediate-intensity anticoagulation. For patients with COVID-19-related acute illness, conditional recommendations were suggested (a) prophylactic-intensity over intermediate-intensity anticoagulation, and (b) therapeutic-intensity over prophylactic-intensity anticoagulation. The panel issued a conditional recommendation suggesting against the use of postdischarge anticoagulant thromboprophylaxis.
CONCLUSIONS: These conditional recommendations were made based on low or very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials for patients with COVID-19.